Cybrexa Therapeutics To Present Data at ASCO 2023 Highlighting First-In-Human, Dose-Finding Study of Lead Candidate CBX-12
May 25, 2023 17:01 ET
|
Cybrexa Therapeutics
Activity and Safety Profile Reinforces Potential of CBX-12 in Solid TumorsFour Objective Responses Observed in Breast and Ovarian Cancers with CBX-12Dose-Limiting Toxicity Identified as...
Cybrexa Appoints Jaya Gautam as Senior Vice President of Technical Operations
April 12, 2023 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., April 12, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Cybrexa Strengthens Drug Development Capabilities with the Addition of Laurie Kenvin to the Company’s Leadership Team and Nick Saccomano to the SAB
February 01, 2023 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Cybrexa Therapeutics Announces the Appointment of Michael N. Needle, MD, as Senior Vice President and Chief Medical Officer
December 15, 2022 07:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Cybrexa Therapeutics Presents Findings from First-in-Human Study of CBX-12 as a Plenary Oral Presentation at 34th EORTC-NCI-AACR Symposium
October 28, 2022 09:25 ET
|
Cybrexa Therapeutics
Positive FIH safety and tolerability data supports advancing CBX-12 into multiple Phase II studiesResults show early signs of efficacy with a favorable safety profile NEW HAVEN, Conn., Oct. 28, 2022...
Cybrexa Therapeutics在第34届EORTC-NCI-AACR研讨会上作全体口头报告，介绍CBX-12的首次人类研究结果
October 28, 2022 09:25 ET
|
Cybrexa Therapeutics
积极的FIH安全性和耐受性数据支持将CBX-12推进到多项II期研究结果显示疗效的早期迹象，伴有良好的安全性 康涅狄格州纽黑文, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Cybrexa...
Cybrexa Therapeutics Presents Findings from First-in-Human Study of CBX-12 as a Plenary Oral Presentation at 34th EORTC-NCI-AACR Symposium
October 28, 2022 09:25 ET
|
Cybrexa Therapeutics
Positive FIH safety and tolerability data supports advancing CBX-12 into multiple Phase II studiesResults show early signs of efficacy with a favorable safety profile NEW HAVEN, Conn., Oct. 28, 2022...
Cybrexa Therapeutics to Present at Upcoming Investor Conferences in June
June 02, 2022 08:30 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., June 02, 2022 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Cybrexa Therapeutics公布数据显示抗原独立肿瘤靶向疗效和强大潜力的早期信号
October 26, 2021 12:26 ET
|
Cybrexa Therapeutics
Cybrexa用于实体肿瘤的主要治疗候选药物CBX-12在既往接受过多种治疗方案的患者人群中显示抗肿瘤活性和强大疗效信号CBX-12和肿瘤免疫疗法联合试验预计将于2022年末启动关于加速批准用于卵巢癌和非小细胞肺癌的计划将根据2022年末开始的2期扩展队列进行评估 康涅狄格州纽黑文, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Cybrexa...
Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy and Powerful Potential of Antigen-Independent Tumor Targeting
October 26, 2021 08:00 ET
|
Cybrexa Therapeutics
CBX-12, Cybrexa’s lead therapeutic candidate for solid tumors, demonstrates anti-tumor activity and robust efficacy signals in a heavily pretreated patient populationCBX-12 and IO therapeutics...